Exchange: NASDAQ·Updated 04:15 PM EDT

ARVN News

News
all
press releases
Ginkgo Bioworks (DNA) Surges 11.1%: Is This an Indication of Further Gains?
Ginkgo Bioworks (DNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks
More News
Can KT-621 Mark a Turning Point for Kymera Therapeutics?
KYMR advances KT-621 in atopic dermatitis and asthma, with earlier-than-expected AD data and potential phase III plans by mid-2027.
Zacks
Arvinas (ARVN) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
Arvinas (ARVN) Upgraded to Strong Buy: Here's What You Should Know
Arvinas (ARVN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
Transcript: Arvinas Q2 2026 Earnings Conference Call
Arvinas (NASDAQ:ARVN) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time access to earningsread more...
Benzinga
Arvinas, Inc. (ARVN) Beats Q2 Earnings and Revenue Estimates
Arvinas (ARVN) delivered earnings and revenue surprises of +1,175.00% and +562.56%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Is Kymera Therapeutics Poised for a Breakthrough With KT-621?
Kymera Therapeutics advances KT-621 enrollment ahead of schedule, bringing pivotal atopic dermatitis data closer as it expands its protein degrader pipeline.
Zacks
uniQure (QURE) Soars 78.4%: Is Further Upside Left in the Stock?
uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Zacks
Twist Bioscience (TWST) Surges 9.3%: Is This an Indication of Further Gains?
Twist Bioscience (TWST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks
Full Transcript: Arvinas Q1 2026 Earnings Call
read more...
Benzinga

Advertisement|Remove ads.